【摘要】 血管内皮生长因子(VEGF)靶向药是目前最常用的抗肿瘤靶向药,在肾癌、结肠癌等肿瘤中被广泛使用,主要分为单抗类、VEGF融合肽和酪氨酸激酶抑制剂(TKI)三类。虽然VEGF靶向药对许多肿瘤都有治疗效果,但是很多报道证实其治疗的同时伴有肾毒性作用。血栓性微血管病变(TMA)和微小病变性肾病(MCD)/局灶节段性肾小球硬化(FSGS)是最常见的两类病理类型。本文将讨论VEGF靶向药导致两类病理类型的机制。更多还原

【Abstract】 Vascular endothelial growth factor(VEGF)-targeted anti-cancer drugs are currently most used in the targeted anti-cancer therapy, and widely used in tumors such as kidney cancer and colon cancer. VEGF-targeted drugs are mainly divided into three classes: anti-VEGF monoclonal antibody, VEGF trap and tyrosine kinase inhibitor(TKI).Although VEGF-targeted drugs have achieved the promising results, renal toxicity has been confirmed many times in related studies. Thrombotic microangiopathy(TMA) and minimally diseased nephropathy(MCD)/focal segmental glomerulosclerosis(FSGS) are the two most common types of pathology. This article would review the mechanism by which VEGF-targeted drugs cause two types of pathology.更多还原